ATE106722T1 - Emulsionen von fluorkohlenwasserstoffen für ''in vivo''-verwendung. - Google Patents

Emulsionen von fluorkohlenwasserstoffen für ''in vivo''-verwendung.

Info

Publication number
ATE106722T1
ATE106722T1 AT88307233T AT88307233T ATE106722T1 AT E106722 T1 ATE106722 T1 AT E106722T1 AT 88307233 T AT88307233 T AT 88307233T AT 88307233 T AT88307233 T AT 88307233T AT E106722 T1 ATE106722 T1 AT E106722T1
Authority
AT
Austria
Prior art keywords
emulsion
fluorocarbon
reduces
osmotic
buffering agents
Prior art date
Application number
AT88307233T
Other languages
English (en)
Inventor
David M Long Jr
Original Assignee
Alliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharma filed Critical Alliance Pharma
Application granted granted Critical
Publication of ATE106722T1 publication Critical patent/ATE106722T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026Blood substitute; Oxygen transporting formulations; Plasma extender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/734Fullerenes, i.e. graphene-based structures, such as nanohorns, nanococoons, nanoscrolls or fullerene-like structures, e.g. WS2 or MoS2 chalcogenide nanotubes, planar C3N4, etc.
    • Y10S977/735Carbon buckyball
    • Y10S977/737Carbon buckyball having a modified surface
    • Y10S977/738Modified with biological, organic, or hydrocarbon material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/895Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT88307233T 1987-08-05 1988-08-05 Emulsionen von fluorkohlenwasserstoffen für ''in vivo''-verwendung. ATE106722T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/082,846 US4987154A (en) 1986-01-14 1987-08-05 Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use

Publications (1)

Publication Number Publication Date
ATE106722T1 true ATE106722T1 (de) 1994-06-15

Family

ID=22173820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88307233T ATE106722T1 (de) 1987-08-05 1988-08-05 Emulsionen von fluorkohlenwasserstoffen für ''in vivo''-verwendung.

Country Status (9)

Country Link
US (1) US4987154A (de)
EP (1) EP0307087B1 (de)
AT (1) ATE106722T1 (de)
CA (1) CA1316820C (de)
DE (1) DE3850012T2 (de)
ES (1) ES2056932T3 (de)
IE (1) IE64245B1 (de)
NO (1) NO179162C (de)
ZA (1) ZA885796B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5284645A (en) * 1987-08-05 1994-02-08 Alliance Pharmaceutical Corp. Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
JPH0372423A (ja) * 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
RU2114637C1 (ru) * 1991-09-17 1998-07-10 Сонус Фармасьютикалз, Инк. Биосовместимая контрастная среда и способ получения ультразвукового изображения
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5350359A (en) * 1992-07-16 1994-09-27 Temple University Of The Commonwealth System Of Higher Education Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5595687A (en) * 1992-10-30 1997-01-21 Thomas Jefferson University Emulsion stability
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
SG52198A1 (en) * 1993-01-25 1998-09-28 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
FR2700696B1 (fr) * 1993-01-28 1995-04-07 Atta Dispersions, émulsions, microémulsions, gels et compositions à usage biomédical comprenant un composé organique fluoré iodé, utilisables notamment comme agent de contraste.
US5635538A (en) * 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
WO1994021303A1 (en) * 1993-03-16 1994-09-29 Alliance Pharmaceutical Corp. Fluorocarbon compositions containing a visible or fluorescent label
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5658962A (en) 1994-05-20 1997-08-19 Minnesota Mining And Manufacturing Company Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
FR2720943B1 (fr) * 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
RU2088223C1 (ru) * 1994-06-29 1997-08-27 Игорь Вячеславович Белов Антиметастатическое средство
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5741248A (en) * 1995-06-07 1998-04-21 Temple University-Of The Commonwealth System Of Higher Education Fluorochemical liquid augmented cryosurgery
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
NZ331460A (en) * 1996-03-05 1998-12-23 Acusphere Inc Microencapsulated fluorinated gases for use as imaging agents
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
US5861175A (en) 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2189974T3 (es) * 1996-09-11 2003-07-16 Imarx Pharmaceutical Corp Procedimientos mejorados para la obtencion de imagenes de diagnostico usando un agente de contraste y un vasodilatador.
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
JP4583510B2 (ja) * 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 無細胞系による酸素輸送の最適化のための方法と組成物
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
DE19721947C2 (de) * 1997-05-21 1999-04-22 Diagnostikforschung Inst Verwendung von pharmazeutischen Zubereitungen, die Partikel, Vesikel oder Polymere sowie nichtsteroidale Antirheumatika und/oder Thrombozytenaggregationshemmer zur Darstellung der Gefäße, Lymphknoten und des Knochenmarks enthalten
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6127430A (en) * 1998-12-16 2000-10-03 3M Innovative Properties Company Microemulsions containing water and hydrofluroethers
US6159917A (en) * 1998-12-16 2000-12-12 3M Innovative Properties Company Dry cleaning compositions containing hydrofluoroether
RU2161122C1 (ru) * 1999-09-10 2000-12-27 Институт молекулярной генетики РАН Способ ускорения окисления оксида азота (no) в гетерогенной среде
RU2206319C2 (ru) 2000-07-20 2003-06-20 Открытое акционерное общество Научно-производственная фирма "Перфторан" Эмульсия перфторорганических соединений для медицинских целей, способ ее приготовления и способы лечения и профилактики заболеваний с ее использованием
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EP1365068B1 (de) * 2002-05-10 2008-05-07 The Procter & Gamble Company Geprägtes Tissue mit abstehenden Oberflächenfasern und Verfahren zu dessen Herstellung
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
US7682603B2 (en) * 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
US20050151112A1 (en) * 2004-01-14 2005-07-14 Minor Barbara H. 1,1,1,2,2,3,3,4,4-Nonafluoro-4-methoxybutane refrigerant compositions comprising hydrofluorocarbon, and uses thereof
JP5019883B2 (ja) 2004-01-16 2012-09-05 カーネギー メロン ユニバーシティ 核磁気共鳴技術のための細胞標識
US7534221B2 (en) 2004-05-24 2009-05-19 The Trustees Of Columbia University In The City Of New York Devices and methods for protecting against distal embolisms
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CN100427142C (zh) * 2005-01-10 2008-10-22 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用助剂及其筛选方法
CN100574811C (zh) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用微粒类助剂及其应用
CN100574809C (zh) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用氟碳乳剂类助剂及其应用
EP2010646A2 (de) 2006-04-14 2009-01-07 Carnegie Mellon University Zellbeschriftung und -quantifizierung für nukleare magnetresonanzverfahren
EP2170975B1 (de) 2007-07-10 2018-05-02 Carnegie Mellon University Zusammensetzungen und verfahren zur herstellung von zellmarkern für kernresonanztechniken
WO2012003457A1 (en) * 2010-07-01 2012-01-05 Mtm Research Llc Anti-fibroblastic fluorochemical emulsion therapies
GB2482911A (en) * 2010-08-20 2012-02-22 Sphere Fluidics Ltd Microdroplet emulsion system
DE102012100859B4 (de) 2012-02-02 2015-12-17 Rwth Aachen Verfahren zum Herstellen dreidimensionaler Strukturen und solche Strukturen
WO2017087775A1 (en) * 2015-11-20 2017-05-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Phase change nanodroplet conjugates for targeted delivery
EP3458037A4 (de) 2016-05-16 2020-01-29 MTM Research, LLC Fluorchemische gerichtete therapien
JP6889535B2 (ja) 2016-10-05 2021-06-18 デンカ株式会社 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3958014A (en) * 1970-09-05 1976-05-18 The Green Cross Corporation Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen
CH604490A5 (de) * 1970-09-05 1978-09-15 Green Cross Corp
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
US3975512A (en) * 1970-12-21 1976-08-17 University Of Illinois Foundation Non-toxic brominated perfluorocarbons radiopaque agents
JPS5331209B2 (de) * 1973-10-05 1978-09-01
US4073879A (en) * 1974-08-26 1978-02-14 University Of Illinois Foundation Brominated perfluorocarbon radiopaque agents
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4146499A (en) * 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
JPS5658032A (en) * 1979-10-09 1981-05-20 Tsudakoma Ind Co Ltd Weft yarn storage apparatus of shuttle less loom
JPS5616314A (en) * 1979-07-20 1981-02-17 Fujitsu Ltd Surface elastic wave filter
JPS5759067A (en) * 1980-09-24 1982-04-09 Mazda Motor Corp Energizing device for glow plug of diesel engine
JPS5759046A (en) * 1980-09-29 1982-04-09 Nissan Motor Co Ltd Air fuel ratio control device
US4439424A (en) * 1981-01-05 1984-03-27 Neomed Inc. Synthetic whole blood
US4343797A (en) * 1981-01-05 1982-08-10 Ecanow Charles S Synthetic whole blood and a method of making the same
JPS5896061A (ja) * 1981-11-30 1983-06-07 Green Cross Corp:The パ−フルオロ環状アミン
US4451251A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
FR2523956A1 (fr) * 1982-03-26 1983-09-30 Ugine Kuhlmann Bis-(perfluoroalkyl)-1,2-ethenes ramifies, leur preparation et leur utilisation comme transporteurs d'oxygene convertisseur electromecanique
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
US4497829A (en) * 1982-07-27 1985-02-05 The University Of Pennsylvania Process for preparing perfluorochemical emulsion artificial blood
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
US4542147A (en) * 1982-08-07 1985-09-17 The Green Cross Corporation Perfluoro-1-azatricyclic amine compound
JPS5960166A (ja) * 1982-09-27 1984-04-06 三菱電機株式会社 凍結装置
JPS5967229A (ja) * 1982-10-08 1984-04-16 Green Cross Corp:The 超音波診断造影剤
JPS59112936A (ja) * 1982-12-21 1984-06-29 Green Cross Corp:The ペルフルオロエ−テル化合物及びその製造法
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides

Also Published As

Publication number Publication date
IE64245B1 (en) 1995-07-26
ES2056932T3 (es) 1994-10-16
EP0307087A1 (de) 1989-03-15
IE882416L (en) 1989-02-05
US4987154A (en) 1991-01-22
NO179162C (no) 1996-08-21
ZA885796B (en) 1990-04-25
NO883456D0 (no) 1988-08-04
DE3850012D1 (de) 1994-07-14
CA1316820C (en) 1993-04-27
DE3850012T2 (de) 1995-01-19
NO883456L (no) 1989-02-06
EP0307087B1 (de) 1994-06-08
NO179162B (no) 1996-05-13

Similar Documents

Publication Publication Date Title
ATE106722T1 (de) Emulsionen von fluorkohlenwasserstoffen für ''in vivo''-verwendung.
DE60121027T2 (de) Lösung zur evaluierung und konservierung
ATE199626T1 (de) Plasma-artige lösung
MX9300398A (es) Sistema de control para suministrar una droga.
DZ1067A1 (fr) Nouvelles préparations pharmaceutiques à emission prolongée.
ATE113832T1 (de) Im wasser schnell suspendierbare pharmazeutische zusammensetzung.
DE4122754A1 (de) Herstellung einer substitutionsloesung fuer die haemofiltration bei dialyseverfahren
Forster et al. Rate limiting processes in the Bohr shift in human red cells
Maude Effects of K and ouabain on fluid transport and cell Na in proximal tubule in vitro
Yunis et al. Amino acid transport in blood cells II. Patterns of transport of some amino acids in mammalian reticulocytes and mature red blood cells
EP0458930B1 (de) STABILISIERUNG VON GLYKOSYLIERTEM t-PA
Hiernickel An improved method for in vitro perfusion of human skin
Howard et al. Iron transport by rat small intestine in vitro: effect of body iron status
DE69509268T2 (de) Lungentransplantat-Konservierungsmittelmischung und Verfahren zur Lebendkonservierung von Lungentransplantaten
JPS6239520A (ja) アスコルビン酸カルシウムの投与装置
ES2122962T3 (es) Derivados de alquileno-dioxibenceno opticamente activos y su uso en terapia.
Case et al. Water and electrolyte secretion by the pancreas
ES2038761T3 (es) Una composicion detergente liquida acuosa.
Mercier et al. Effects of parathyroid hormone and urinary phosphate on collecting duct hydrogen secretion
Michel One hundred years of Starling's hypothesis
GB1024408A (en) Improvements in or relating to beverage concentrates
Good et al. Ammonia absorption by the thick ascending limb of Henle’s loop
Jaques The Howell theory of blood coagulation: a record of the pernicious effects of a false theory
Newman Some factors influencing the rate of metabolism of ethyl alcohol
FR2656527B1 (fr) Solution d'irrigation oculaire utilisee en therapeutique pour la protection endotheliale et la conservation de la cornee.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time